Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

Gregory M. Springett

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5047712976. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 9 papers · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper

Papers 22

  1. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Co-author DOI 10.1097/coc.0000000000000261↗
  2. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  3. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  4. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-5006-1↗
  5. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Co-author DOI 10.21037/jgo.2016.03.15↗
  6. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2015.075↗
  7. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2814-8↗
  8. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Co-author DOI 10.1007/s00464-015-4075-3↗
  9. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-015-9734-z↗
  10. Resected pancreatic cancer outcomes in the elderly. Co-author DOI 10.1016/j.jgo.2014.11.005↗
  11. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2015.07.018↗
  12. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Co-author DOI 10.1097/rlu.0000000000000837↗
  13. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  14. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… Co-author DOI 10.3109/0284186x.2015.1004367↗
  15. Outcomes of resected pancreatic cancer in patients age ≥70. Co-author DOI 10.3978/j.issn.2078-6891.2015.038↗
  16. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. First author DOI 10.1002/cncr.28543↗
  17. Novel pancreatic cancer vaccines could unleash the army within. Co-author DOI 10.1177/107327481402100311↗
  18. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. First author DOI 10.1016/j.ijrobp.2013.02.022↗
  19. Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma. Last author PMID 22706548↗
  20. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Last author DOI 10.1002/jso.21954↗
  21. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗
  22. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Co-author PMID 22368736↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sarah E. Hoffe · 17 shared papers, 2011–2018 · strength 0.87
  2. Mokenge Peter Malafa · 15 shared papers, 2011–2017 · strength 0.72
  3. Pamela Joy Hodul · 14 shared papers, 2011–2017 · strength 0.68
  4. Ravi Shridhar · 13 shared papers, 2011–2017 · strength 0.65
  5. Jessica M. Frakes · 7 shared papers, 2015–2017 · strength 0.40
  6. Eric A. Mellon · 7 shared papers, 2013–2017 · strength 0.38
  7. Tobin Joel Crill Strom · 7 shared papers, 2015–2017 · strength 0.38
  8. Amit Mahipal · 4 shared papers, 2015–2018 · strength 0.26
  9. Kenneth Lee Meredith · 5 shared papers, 2013–2017 · strength 0.24
  10. Barbara Ann Centeno · 5 shared papers, 2011–2017 · strength 0.23
  11. Michael David Chuong · 5 shared papers, 2011–2016 · strength 0.23
  12. Richard D. Kim · 3 shared papers, 2015–2018 · strength 0.20
  13. Monique Z. Sajjad · 1 shared paper, 2018 · strength 0.10
  14. Jason B. Klapman · 2 shared papers, 2011–2015 · strength 0.08
  15. William H. Jin · 1 shared paper, 2017 · strength 0.07
  16. Chenwi M. Ambe · 1 shared paper, 2015 · strength 0.06
  17. Yaman Suleiman · 1 shared paper, 2015 · strength 0.05
  18. Manish R. Patel · 2 shared papers, 2011 · strength 0.05
  19. Thomas J. Hayman · 1 shared paper, 2015 · strength 0.05
  20. Nishi Kothari · 1 shared paper, 2015 · strength 0.05
  21. Dung‐Tsa Chen · 1 shared paper, 2016 · strength 0.05
  22. José M. Pimiento · 1 shared paper, 2016 · strength 0.05
  23. Omar Maen Rashid · 1 shared paper, 2016 · strength 0.05
  24. Domenico Coppola · 1 shared paper, 2015 · strength 0.05
  25. Deirdre Jill Cohen · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.